{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:53:48Z","timestamp":1791161628509,"version":"4.1.0"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/gme.0b013e3181c4f1d6","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T05:34:37Z","timestamp":1268890477000},"page":"642-653","source":"Crossref","is-referenced-by-count":51,"title":["Endometrial safety"],"prefix":"10.1097","volume":"17","author":[{"given":"JoAnn V.","family":"Pinkerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20210227","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice.","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-32-20210227","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.coph.2003.07.003","article-title":"Estrogens in postmenopausal women: recent insights.","volume":"3","author":"Constantine","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"R5-32-20210227","first-page":"1451","article-title":"Early Breast Cancer Trialists' Collaborative Group.","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"R6-32-20210227","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R7-32-20210227","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"R8-32-20210227","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1196\/annals.1365.034","article-title":"The cardiovascular effects of selective estrogen receptor modulators.","volume":"1092","author":"Christodoulakos","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R9-32-20210227","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jnci\/85.17.1398","article-title":"Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.","volume":"85","author":"Rutqvist","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R10-32-20210227","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R11-32-20210227","first-page":"418","article-title":"Selective estrogen receptor modulators: clinical spectrum.","volume":"20","author":"Cosman","year":"1999","journal-title":"Endocr Rev"},{"key":"R12-32-20210227","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/01.gme.0000222332.31101.42","article-title":"Not all SERMs are created equal.","volume":"13","author":"Goldstein","year":"2006","journal-title":"Menopause"},{"key":"R13-32-20210227","first-page":"437","article-title":"Recent advances in estrogen receptor modulators.","volume":"8","author":"Henke","year":"2005","journal-title":"Curr Opin Drug Discov Devel"},{"key":"R14-32-20210227","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1196\/annals.1290.040","article-title":"The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.","volume":"997","author":"Draper","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R15-32-20210227","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/1071557600007001S05","article-title":"Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen.","volume":"7","author":"McDonnell","year":"2000","journal-title":"J Soc Gynecol Investig"},{"key":"R16-32-20210227","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00042192-200209000-00012","article-title":"Controversy about uterine effects and safety of SERMs: the saga continues.","volume":"9","author":"Goldstein","year":"2002","journal-title":"Menopause"},{"key":"R17-32-20210227","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2174\/1381612023393404","article-title":"SERMs: evolutionary chemistry, revolutionary biology.","volume":"8","author":"Miller","year":"2002","journal-title":"Curr Pharm Des"},{"key":"R18-32-20210227","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2004.03.006","article-title":"The molecular determinants of estrogen receptor pharmacology.","volume":"48","author":"McDonnell","year":"2004","journal-title":"Maturitas"},{"key":"R19-32-20210227","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/edrv.20.3.0370","article-title":"Estrogen receptor null mice: what have we learned and where will they lead us?","volume":"20","author":"Couse","year":"1999","journal-title":"Endocr Rev"},{"key":"R20-32-20210227","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors and .","volume":"138","author":"Kuiper","year":"1997","journal-title":"Endocrinology"},{"key":"R21-32-20210227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1258\/175404507780456791","article-title":"The future of the new selective estrogen receptor modulators.","volume":"13","author":"Palacios","year":"2007","journal-title":"Menopause Int"},{"key":"R22-32-20210227","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0002-9378(79)90289-8","article-title":"Effects of long-term estrogen replacement therapy. II. Neoplasia.","volume":"133","author":"Hammond","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"R23-32-20210227","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","article-title":"Association of exogenous estrogen and endometrial carcinoma.","volume":"293","author":"Smith","year":"1975","journal-title":"N Engl J Med"},{"key":"R24-32-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00042192-200310020-00003","article-title":"Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society.","volume":"10","year":"2003","journal-title":"Menopause"},{"key":"R25-32-20210227","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0015-0282(01)01792-7","article-title":"Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding.","volume":"75","author":"Archer","year":"2001","journal-title":"Fertil Steril"},{"key":"R26-32-20210227","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/cmt.4.2.110.119","article-title":"Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable?","volume":"4","author":"Lobo","year":"2001","journal-title":"Climacteric"},{"key":"R27-32-20210227","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00042192-200512010-00018","article-title":"The case for less-than-monthly progestogen in women on HT: is transvaginal ultrasound the key?","volume":"12","author":"Goldstein","year":"2005","journal-title":"Menopause"},{"key":"R28-32-20210227","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.gme.0000185119.74706.7b","article-title":"Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy.","volume":"12","author":"Odmark","year":"2005","journal-title":"Menopause"},{"key":"R29-32-20210227","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials.","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"R30-32-20210227","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2004.03.048","article-title":"Endometrial pathologies associated with postmenopausal tamoxifen treatment.","volume":"94","author":"Cohen","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R31-32-20210227","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0020-7292(96)90115-0","article-title":"ACOG committee opinion. Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on Gynecologic Practice.","volume":"53","year":"1996","journal-title":"Int J Gynaecol Obstet"},{"key":"R32-32-20210227","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/sonc.2001.23492","article-title":"Tamoxifen to raloxifene and beyond.","volume":"28","author":"O'Regan","year":"2001","journal-title":"Semin Oncol"},{"key":"R33-32-20210227","first-page":"855","article-title":"Tamoxifen treatment and gynecologic side effects: a review.","volume":"97","author":"Mourits","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R34-32-20210227","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1749-6632.2001.tb04027.x","article-title":"The effect of SERMs on the endometrium.","volume":"949","author":"Goldstein","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"R35-32-20210227","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1525-1438.2001.01046.x","article-title":"Current molecular aspects of the carcinogenesis of the uterine endometrium.","volume":"11","author":"Inoue","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"R36-32-20210227","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/jnci\/djh007","article-title":"Risk of malignant mixed Mullerian tumors after tamoxifen therapy for breast cancer.","volume":"96","author":"Curtis","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R37-32-20210227","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2002.20.11.2758","article-title":"Association of tamoxifen and uterine sarcoma.","volume":"20","author":"Wickerham","year":"2002","journal-title":"J Clin Oncol"},{"key":"R38-32-20210227","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cncr.22734","article-title":"Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen.","volume":"110","author":"Saadat","year":"2007","journal-title":"Cancer"},{"key":"R39-32-20210227","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2008.08.035","article-title":"Relationship between tamoxifen use and high risk endometrial cancer histologic types.","volume":"112","author":"Bland","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R40-32-20210227","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-007-9823-1","article-title":"Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.","volume":"112","author":"Hoogendoorn","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R41-32-20210227","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R42-32-20210227","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.","volume":"9","author":"Saphner","year":"1991","journal-title":"J Clin Oncol"},{"key":"R43-32-20210227","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.1991.00400090120021","article-title":"Symptoms associated with tamoxifen treatment in postmenopausal women.","volume":"151","author":"Love","year":"1991","journal-title":"Arch Intern Med"},{"key":"R44-32-20210227","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(05)72466-1","article-title":"Occurrence of stroke with tamoxifen in NSABP B-24.","volume":"355","author":"Dignam","year":"2000","journal-title":"Lancet"},{"key":"R45-32-20210227","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial.","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R46-32-20210227","first-page":"1259","article-title":"Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma.","volume":"28","author":"Lindahl","year":"2008","journal-title":"Anticancer Res"},{"key":"R47-32-20210227","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2005.09.007","article-title":"Toremifene: an evaluation of its safety profile.","volume":"15","author":"Harvey","year":"2006","journal-title":"Breast"},{"key":"R48-32-20210227","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1005891506092","article-title":"A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group.","volume":"45","author":"Gershanovich","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"R49-32-20210227","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.1995.13.10.2556","article-title":"Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.","volume":"13","author":"Hayes","year":"1995","journal-title":"J Clin Oncol"},{"key":"R50-32-20210227","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1997.375","article-title":"Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'Nordic' phase III study.","volume":"76","author":"Pyrhonen","year":"1997","journal-title":"Br J Cancer"},{"key":"R52-32-20210227","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"R53-32-20210227","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1067\/mob.2000.104768","article-title":"Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women.","volume":"182","author":"Fugere","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R54-32-20210227","first-page":"95","article-title":"A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium.","volume":"95","author":"Goldstein","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R55-32-20210227","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over eight years in a clinical trial setting.","volume":"21","author":"Martino","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R56-32-20210227","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0b013e318031a83d","article-title":"The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.","volume":"14","author":"Stovall","year":"2007","journal-title":"Menopause"},{"key":"R57-32-20210227","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","article-title":"Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.","volume":"13","author":"Lufkin","year":"1998","journal-title":"J Bone Miner Res"},{"key":"R58-32-20210227","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.GME.0000058772.59606.2A","article-title":"Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.","volume":"10","author":"Jolly","year":"2003","journal-title":"Menopause"},{"key":"R59-32-20210227","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1068-607X(98)00066-3","article-title":"Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women.","volume":"5","author":"Glusman","year":"1998","journal-title":"Prim Care Update Ob Gyns"},{"key":"R60-32-20210227","first-page":"558","article-title":"Adverse events reported by postmenopausal women in controlled trials with raloxifene.","volume":"93","author":"Davies","year":"1999","journal-title":"Obstet Gynecol"},{"key":"R61-32-20210227","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5122(99)00090-0","article-title":"Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.","volume":"34","author":"Cohen","year":"2000","journal-title":"Maturitas"},{"key":"R62-32-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"R63-32-20210227","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"R64-32-20210227","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2007.14.0921","article-title":"Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.","volume":"26","author":"DeMichele","year":"2008","journal-title":"J Clin Oncol"},{"key":"R65-32-20210227","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.GME.0000087981.28957.CF","article-title":"Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.","volume":"11","author":"Davis","year":"2004","journal-title":"Menopause"},{"key":"R66-32-20210227","first-page":"45","article-title":"Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.","volume":"10","author":"Pinkerton","year":"2003","journal-title":"Menopause"},{"key":"R67-32-20210227","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7863\/jum.1999.18.7.503","article-title":"Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene.","volume":"18","author":"Fleischer","year":"1999","journal-title":"J Ultrasound Med"},{"key":"R68-32-20210227","first-page":"21","article-title":"","volume":"2431","year":"1999","journal-title":"SCRIP"},{"key":"R69-32-20210227","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/13697130500117946","article-title":"Urogenital effects of selective estrogen receptor modulators: a systematic review.","volume":"8","author":"Albertazzi","year":"2005","journal-title":"Climacteric"},{"key":"R70-32-20210227","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1067\/mob.2002.123938","article-title":"Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study.","volume":"187","author":"Goldstein","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R71-32-20210227","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/00016340500345691","article-title":"What can be learned from the levormeloxifene experience?","volume":"85","author":"Ravn","year":"2006","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R72-32-20210227","first-page":"18","article-title":"","volume":"2374","year":"1998","journal-title":"SCRIP"},{"key":"R74-32-20210227","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"R76-32-20210227","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"R77-32-20210227","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"key":"R78-32-20210227","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","article-title":"Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.","volume":"105","author":"Ronkin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R79-32-20210227","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/gme.0b013e3181a816be","article-title":"Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"R80-32-20210227","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.","volume":"16","author":"Archer","year":"2009","journal-title":"Menopause"},{"key":"R81-32-20210227","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2003.06.108","article-title":"Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.","volume":"21","author":"Buzdar","year":"2003","journal-title":"J Clin Oncol"},{"key":"R82-32-20210227","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/annonc\/mdg368","article-title":"Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.","volume":"14","author":"Baselga","year":"2003","journal-title":"Ann Oncol"},{"key":"R83-32-20210227","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2008-2143","article-title":"Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.","volume":"94","author":"Bolognese","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R86-32-20210227","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1517\/14656560903127241","article-title":"Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.","volume":"10","author":"Gennari","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R90-32-20210227","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"key":"R91-32-20210227","first-page":"448","article-title":"Ospemifene Hormos.","volume":"5","author":"Gennari","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"R96-32-20210227","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"R97-32-20210227","first-page":"84a","article-title":"Preclinical profile of WAY-140424, a third-generation selective estrogen receptor modulator with an improved therapeutic potential.","volume":"8","author":"Komm","year":"2001","journal-title":"J Soc Gynecol Investig"},{"key":"R98-32-20210227","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.","volume":"949","author":"Komm","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"R99-32-20210227","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R100-32-20210227","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial.","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R101-32-20210227","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.2001.19.7.2002","article-title":"Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.","volume":"19","author":"Munster","year":"2001","journal-title":"J Clin Oncol"},{"key":"R103-32-20210227","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0090-8258(03)00343-3","article-title":"Arzoxifene as therapy for endometrial cancer.","volume":"90","author":"Burke","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R104-32-20210227","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-8258(03)00203-8","article-title":"A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.","volume":"90","author":"McMeekin","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R107-32-20210227","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1200\/JCO.2006.09.5992","article-title":"Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.","volume":"25","author":"Deshmane","year":"2007","journal-title":"J Clin Oncol"},{"key":"R108-32-20210227","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/13543784.15.3.317","article-title":"Arzoxifene: the development and clinical outcome of an ideal SERM.","volume":"15","author":"Munster","year":"2006","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/gme.0b013e3181c4f1d6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:23Z","timestamp":1786040423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-201017030-00032"}},"subtitle":["a key hurdle for selective estrogen receptor modulators in development"],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3181c4f1d6","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}